Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control

Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control

Abstract Background Immune checkpoint inhibitors (CPIs) have revolutionized oncologic therapy but can lead to immune‐related adverse events (irAEs). Corticosteroids are first‐line treatment with escalation to biologic immunosuppression in refractory cases. CPI‐related gastroenterocolitis (GEC) affec...

Full description

Bibliographic Details
Main Authors: Michael S. Hughes, Hui Zheng, Leyre Zubiri, Gabriel E. Molina, Steven T. Chen, Meghan J. Mooradian, Ian M. Allen, Kerry L. Reynolds, Michael Dougan
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Cancer Medicine
Subjects:
adverse effects
checkpoint inhibition
colitis
CTLA‐4
hospitalization
immunotherapy
Online Access:https://doi.org/10.1002/cam4.2397

Internet

https://doi.org/10.1002/cam4.2397

Similar Items